Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongmei Sun

Showing results (211-220 of 229) with videos related to

Pageof 23
Sort By:
The Lancet. Oncology|March 13, 2026
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trialHua Zhong, Jing Wang, Runxiang Yang, et al.
Cancer Cell|January 5, 2024
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)Caicun Zhou, Yanping Hu, Ekaterine Arkania, et al.
Immunology|November 12, 2025
Plasma Protein Fluctuation Trajectories Over 15 Years Before Rheumatoid Arthritis OnsetChen Sun, Jiacheng Wang, Wei She, et al.
Cancer Cell|March 6, 2026
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan, Yuping Sun, Qiming Wang, et al.
Journal of Bone Oncology|February 25, 2025
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumorsMingchuan Zhao, Xichun Hu, Pengpeng Zhuang, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
The evolutionary tale of lilies: Giant genomes derived from transposon insertions and polyploidizationSujuan Xu, Runzhou Chen, Xinqi Zhang, et al.
Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
JAMA Oncology|February 8, 2024
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence TrialShaohua Zhang, Yongmei Yin, Hailin Xiong, et al.
Pageof 23

Showing results (211-220 of 229) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|March 13, 2026
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trialHua Zhong, Jing Wang, Runxiang Yang, et al.
Cancer Cell|January 5, 2024
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)Caicun Zhou, Yanping Hu, Ekaterine Arkania, et al.
Immunology|November 12, 2025
Plasma Protein Fluctuation Trajectories Over 15 Years Before Rheumatoid Arthritis OnsetChen Sun, Jiacheng Wang, Wei She, et al.
Cancer Cell|March 6, 2026
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan, Yuping Sun, Qiming Wang, et al.
Journal of Bone Oncology|February 25, 2025
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumorsMingchuan Zhao, Xichun Hu, Pengpeng Zhuang, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Innovation (Cambridge (Mass.))|November 12, 2024
The evolutionary tale of lilies: Giant genomes derived from transposon insertions and polyploidizationSujuan Xu, Runzhou Chen, Xinqi Zhang, et al.
Cancer Communications (London, England)|May 29, 2025
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trialYing Cheng, Shuang Zhang, Liang Han, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
JAMA Oncology|February 8, 2024
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence TrialShaohua Zhang, Yongmei Yin, Hailin Xiong, et al.
Pageof 23